BioSpace News Archive

Atara Chief Executive Officer Pascal Touchon believes the positive momentum will continue for his company through the coming months of 2021.

An investigational oral MK2 inhibitor from Aclaris Therapeutics was safe and associated with promising reductions in inflammatory markers in a 12-week, Phase II a study of patients with moderate to severe rheumatoid arthritis.

Tiziana Life Sciences plc provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary shares on the standard listing segment of the Official List of the Financial Conduct Authority and admission to trading on the main market for listed securities of London Stock Exchange plc .

Calliditas Therapeutics AB announced it will provide information on the near-term clinical development plans for setanaxib in primary biliary cholangitis and oncology.

Home testing products allow an individual to test a disease condition at home. The tests done at home are quick and confidential.

The physical injuries such as, burns, dislocations, fractures, sprains and strains caused by any external source are termed as trauma.

Guidewires sales are poised to grow at 6.5% y-o-y in 2021, subsequent to an ambiguous year in 2020.

Elcam medical, a leading producer of medical devices, to invest $1.5 million in Serenno Medical and will also manufacture Serenno’s urine output monitoring device for early detection and prevention of acute kidney injury

Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%